Pre-notice of a tender for a Managed Service Contract (MSC) for Molecular Diagnostics and future sub-categories of Microbiology

Concepts

• pathology services
• southampton
• portsmouth
• newport
• poole
• basingstoke
• salisbury
• dorchester
• wpl
• molecular diagnostics

Location

SOUTH EAST (ENGLAND)

Description

This Notice is to inform potential bidders that Wessex NHS Procurement Limited (WPL) will be advertising a tender opportunity in June 2022 for the provision of a Managed Service Contract (MSC) for Molecular Diagnostics on behalf of the Southern Counties Pathology Network (SCP). WPL will require potential bidders to have the capability and capacity to undertake compliant procurement responsibility for both mini competitions and tenders that adhere to Public Contracts Regulations 2015 (PCR 2015) (and/or the latest Procurement legislation applicable throughout the duration of the contract). These to include future sub-categories of Microbiology as managed service contracts, to be included within the main managed service contract, on behalf of SCP.

Total Quantity or Scope

Southern Counties Pathology (SCP) is a procurement consortium of NHS and Foundation Trusts that forms the NHS Improvement South 6 Pathology Network: SCP consists of: Isle of Wight NHS Trust Hampshire Hospitals NHS Foundation Trust Dorset County Hospital NHS Foundation Trust and University Hospitals Dorset NHS Foundation Trust comprise One Dorset Pathology Portsmouth Hospitals University NHS Trust Salisbury NHS Foundation Trust University Hospitals Southampton NHS Foundation Trust (Not participating in this tender) SCP is a procurement collaboration which aims to deliver the procurement objectives of the South 6 Pathology Network which are: To enable the future formation of a consolidated pathology network over the next ten years by standardising our suppliers and the equipment they supply to us, to deliver our high-volume routine pathology activity and to achieve cost savings by reducing non-pay spend on our high-volume routine pathology activity. There has been expansion of molecular techniques within the diagnostic laboratory environment at all partner trusts within the SCP network in recent years. Drivers for change include: Continual growth in the number of different molecular assays being performed Clinical requirements for greater molecular testing A need for improvement in turnaround times Better management of the increasing number of different platforms, suppliers and contracts A dramatic shift in the requirement for rapid and largescale testing of respiratory viruses The primary goals considered when developing the scope of this requirement are: Distribute molecular services based on clinical need and urgency Where possible, rationalise non urgent work at fewer sites Repatriate currently referred work into the SCP network where cost effective Consider the design of future services where COVID testing regimes can be flexed to respond to UKHSA/Government directives A regional molecular service which can respond rapidly Access to the latest technology Integration and interfacing to support the development of Pathology network operations Respiratory virus testing including covid and development of the future service delivery model. SCP will utilise the award of a new regional managed service contract (MSC) as an opportunity to support the development of regional respiratory virus testing. This will provide flexibility as further guidance and policy is defined Contract value The estimated value of this MSC for Molecular Diagnostics is £36,000,000. The estimated value of all sub-categories of Microbiology, including Molecular Diagnostics is £118,000,000. Any future contracts awarded will complete co-terminus with the overarching Pathology contract within the SCP network on 19th July 2031. WPL is running the procurement for a managed service contract for molecular diagnostics on behalf of SCP. WPL is a newly formed joint venture subsidiary of University Hospital Southampton NHS Foundation Trust and Hampshire Hospitals NHS Foundation Trust This PIN is to inform the market that a contract notice will be published during June 2022 providing further information regarding this opportunity. This Tender will be run as a Competitive Procedure with Negotiation however the contracting authority reserves the right to award a contract based on initial tenders without conducting negotiations. Potential bidders will be invited to complete a Selection Questionnaire (SQ) Stage 1 that will be evaluated and scored and only the top 3 scoring potential bidders will proceed to the Invitation to Tender (ITT) Stage 2. If a potential bidder has an equal score within the Top 3 then they also proceed to the ITT Stage 2. Potential bidders who fail to achieve a Top 3 score will not be invited to the ITT Stage 2 and will leave the procurement process at Stage 1. This PIN is for information only and we are unable to respond for further requests for information

CPV Codes

• 85111800 - Pathology services

Indicators

Other Information

Additional sub-categories may include but is not limited to: Blood culture diagnostics, Procurement of culture media (conventional & chromogenic), Urine analysis (microscopy & culture), Antimicrobial susceptibility testing, Microbial identification systems, Automation for microbial culture Mycobacterial diagnosis. Further information will be provided in the Contract Notice To view this notice, please click here: https://www.delta-esourcing.com/delta/viewNotice.html?noticeId=684732166 GO Reference: GO-2022517-PRO-20149200